Overview

Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate, etc.) and safety of precision neoadjuvant or conversion therapy.

Eligibility

Inclusion Criteria:

• Patients with histopathologic diagnosis of salivary gland carcinoma
  • The tumor tissues were subjected to HER2/NTRK/AR/TROP-2 immunohistochemical staining.
    • ECOG physical status 0 or 1 score in the 3 days before the first medication of the study treatment;
      • Age 18 or older - no upper limit;
        • Life expectancy is more than 3 months; ⑥Have at least one measurable lesion according to RECIST1.1 standards; ⑦Women of childbearing age must have a negative pregnancy test within 7 days before the first medication, and agree to receive the necessary contraceptive measures;

          ⑧The patient must have adequate liver, kidney, bone marrow, heart and lung and other organ functions:

          ⑨Understanding and voluntarily signing informed consent prior to performing any research-related evaluation/operation;

          ⑩Ability to comply with research visit schedules and other programmatic requirements.

Exclusion Criteria:

• Known hypersensitivity or delayed anaphylaxis to any agents in this trial;
  • Major surgery had been performed within 4 weeks prior to the start of the study and did not fully recover;
    • Have received a live vaccine within 4 weeks before the start of the study or plan to receive any vaccine during the study period ;
      • To study the occurrence of arterial/venous thrombosis events within 6 months before medication;
        • Major cardiovascular diseases;
          • Is suffering from uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, acute lung disease, interstitial lung disease, cirrhosis, etc.;
            • Is suffering from an active infection that requires systemic treatment;
              • History of active tuberculosis; ⑨ Positive human immunodeficiency virus (HIV) test result; ⑩ Patients with chronic hepatitis B or active hepatitis C. ⑪Conditions that the investigator believes will affect the safety or compliance of the drug therapy in this study ⑫Female/male who is pregnant or breastfeeding or who intends to give birth;